Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
The presentation will be available on-demand beginning on
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
212-915-2578
Source: Soleno Therapeutics